Nuzenio

Tradingview Ligand Pharmaceuticals

Tradingview Ligand Pharmaceuticals entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 10 latest news signals 1 publisher sources 100/100 entity strength

Latest news

Ligand Pharmaceuticals 2Q 2026: Revenue $63.69M, EPS $2.22— 10-Q Summary - TradingViewTradingView · Fri, 07 Aug 2026 20:11:01 GMTLigand Pharmaceuticals Q2 Earnings Call Highlights - TradingViewTradingView · Thu, 06 Aug 2026 21:03:55 GMTEnterprise value to EBIT forward of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingViewTradingView · Thu, 06 Aug 2026 20:40:05 GMTLigand Pharmaceuticals Incorporated Stock 12‑Month Price Target Raised to $343.3, Implies 13% Upside - TradingViewTradingView · Thu, 06 Aug 2026 20:23:23 GMTLigand Pharmaceuticals Incorporated reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Thu, 06 Aug 2026 13:32:01 GMTLGND: Q2 2026 royalty revenue up 32%, adjusted EPS guidance raised after XOMA acquisition and debt financing - TradingViewTradingView · Thu, 06 Aug 2026 12:28:27 GMTLGND: Q2 2026 delivered strong royalty and EPS growth, with XOMA acquisition doubling the portfolio - TradingViewTradingView · Thu, 06 Aug 2026 11:34:47 GMTLigand reports Q2 2026: Revenue $63.7M, Royalties $48.0M, GAAP EPS $2.22, Adjusted EPS $2.37 - TradingViewTradingView · Thu, 06 Aug 2026 11:13:01 GMT

Timeline

Fri, 07 Aug 2026 20:11:01 GMTLigand Pharmaceuticals 2Q 2026: Revenue $63.69M, EPS $2.22— 10-Q Summary - TradingView
Thu, 06 Aug 2026 21:03:55 GMTLigand Pharmaceuticals Q2 Earnings Call Highlights - TradingView
Thu, 06 Aug 2026 20:40:05 GMTEnterprise value to EBIT forward of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Thu, 06 Aug 2026 20:23:23 GMTLigand Pharmaceuticals Incorporated Stock 12‑Month Price Target Raised to $343.3, Implies 13% Upside - TradingView
Thu, 06 Aug 2026 13:32:01 GMTLigand Pharmaceuticals Incorporated reports results for the quarter ended June 30 - Earnings Summary - TradingView
Thu, 06 Aug 2026 12:28:27 GMTLGND: Q2 2026 royalty revenue up 32%, adjusted EPS guidance raised after XOMA acquisition and debt financing - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tradingview Ligand Pharmaceuticals.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

1 distinct publisher/source names are currently connected to this entity page.